Literature DB >> 8788503

Serotonergic regulation of renin and prolactin secretion.

L D Van de Kar1, P A Rittenhouse, Q Li, A D Levy.   

Abstract

Drugs that, directly or indirectly produce activation of serotonin (5-HT) receptors increase plasma concentrations of both prolactin and renin. The serotonergic regulation of prolactin and renin secretion share several common characteristics. Serotonergic neurons originating in the dorsal raphe and terminating in the hypothalamus stimulate the secretion of both prolactin and renin. Destruction of cells in the hypothalamic paraventricular nucleus (PVN) inhibits both the prolactin and renin responses to 5-HT agonists and 5-HT-releasing drugs. Activation of 5-HT2 receptors increases the secretion of both prolactin and renin, while activation of other 5-HT receptor subtypes has differential effects on these hormones. However, there are also differences between the serotonergic mechanisms that regulate the secretion of prolactin and renin. Activation of 5-HT1A receptors increases the secretion of prolactin but not of renin. In addition, activation of peripheral 5-HT2 receptors stimulates the secretion of renin, while activation of peripheral 5-HT3 receptors increases plasma levels of prolactin but not renin. In humans, the effect of 5-HT-releasing drugs and 5-HT agonists on plasma prolactin concentrations has been studied to a greater extent than effects on most other hormones. In contrast, the renin response to 5-HT agonists and 5-HT releasers has not been well characterized in humans. Because of the important role of the renin-angiotensin system in cardiovascular regulation, studies on the serotonergic regulation of renin release in humans could increase our understanding of cardiovascular disorders associated with altered serotonergic function. Examples include anxiety and consequences of cocaine abuse. In conclusion, comparing the serotonergic regulation of prolactin and renin secretion indicates similarities that might shed light on common brain mechanisms that regulate neuroendocrine function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8788503     DOI: 10.1016/0166-4328(96)00097-6

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  9 in total

1.  Peripheral markers of central fatigue in trained and untrained during uncompensable heat stress.

Authors:  Heather E Wright; Glen A Selkirk; Shawn G Rhind; Tom M McLellan
Journal:  Eur J Appl Physiol       Date:  2011-07-07       Impact factor: 3.078

2.  The impact of increased blood lactate on serum S100B and prolactin concentrations in male adult athletes.

Authors:  Stefanie Schulte; Thorsten Schiffer; Billy Sperlich; Axel Knicker; Leslie W Podlog; Heiko K Strüder
Journal:  Eur J Appl Physiol       Date:  2012-09-29       Impact factor: 3.078

3.  Responses to exercise in the heat related to measures of hypothalamic serotonergic and dopaminergic function.

Authors:  Mathew W Bridge; Andrew S Weller; Mark Rayson; David A Jones
Journal:  Eur J Appl Physiol       Date:  2003-04-09       Impact factor: 3.078

Review 4.  Ovarian steroids and serotonin neural function.

Authors:  C L Bethea; M Pecins-Thompson; W E Schutzer; C Gundlah; Z N Lu
Journal:  Mol Neurobiol       Date:  1998-10       Impact factor: 5.590

5.  Brain serotonergic and dopaminergic modulators, perceptual responses and endurance exercise performance following caffeine co-ingested with a high fat meal in trained humans.

Authors:  Marios P Hadjicharalambous; Liam P Kilduff; Yannis P Pitsiladis
Journal:  J Int Soc Sports Nutr       Date:  2010-05-27       Impact factor: 5.150

Review 6.  What can we learn from rodents about prolactin in humans?

Authors:  Nira Ben-Jonathan; Christopher R LaPensee; Elizabeth W LaPensee
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

Review 7.  The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.

Authors:  J Peuskens; L Pani; J Detraux; M De Hert
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

8.  Potential Biomarkers of Peripheral and Central Fatigue in High-Intensity Trained Athletes at High-Temperature: A Pilot Study with Momordica charantia (Bitter Melon).

Authors:  Jae-Jun Kwak; Jang Soo Yook; Min-Seong Ha
Journal:  J Immunol Res       Date:  2020-06-08       Impact factor: 4.818

9.  Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.

Authors:  M B Jameson; P I Thompson; B C Baguley; B D Evans; V J Harvey; D J Porter; M R McCrystal; M Small; K Bellenger; L Gumbrell; G W Halbert; P Kestell
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.